These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 24555991)

  • 1. CRISPR-based technologies: prokaryotic defense weapons repurposed.
    Terns RM; Terns MP
    Trends Genet; 2014 Mar; 30(3):111-8. PubMed ID: 24555991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-guided genome editing à la carte.
    Horvath P; Barrangou R
    Cell Res; 2013 Jun; 23(6):733-4. PubMed ID: 23478298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An history of the CRISPR-Cas systems discovery].
    Pourcel C
    Biol Aujourdhui; 2017; 211(4):247-254. PubMed ID: 29956651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and Validation of Spacer Sequences for CRISPR-Cas9 Genome Editing and Transcription Regulation in Bacteria.
    Grenier F; Lucier JF; Rodrigue S
    Methods Mol Biol; 2015; 1334():233-44. PubMed ID: 26404154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas RNA Targeting Using Transient Cas13a Expression in Nicotiana benthamiana.
    Sharma V; Zheng W; Huang J; Cook DE
    Methods Mol Biol; 2021; 2170():1-18. PubMed ID: 32797447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology.
    Hashemi A
    Curr Gene Ther; 2018; 18(2):115-124. PubMed ID: 29473500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 advances engineering of microbial cell factories.
    Jakočiūnas T; Jensen MK; Keasling JD
    Metab Eng; 2016 Mar; 34():44-59. PubMed ID: 26707540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting CRISPR/Cas systems for biotechnology.
    Sampson TR; Weiss DS
    Bioessays; 2014 Jan; 36(1):34-8. PubMed ID: 24323919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR: From Prokaryotic Immune Systems to Plant Genome Editing Tools.
    Bandyopadhyay A; Mazumdar S; Yin X; Quick WP
    Adv Exp Med Biol; 2017; 1016():101-120. PubMed ID: 29130156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of CRISPR/Cas System to Bacterial Metabolic Engineering.
    Cho S; Shin J; Cho BK
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous Type I CRISPR-Cas: From Foreign DNA Defense to Prokaryotic Engineering.
    Zheng Y; Li J; Wang B; Han J; Hao Y; Wang S; Ma X; Yang S; Ma L; Yi L; Peng W
    Front Bioeng Biotechnol; 2020; 8():62. PubMed ID: 32195227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III CRISPR-Cas Systems: Deciphering the Most Complex Prokaryotic Immune System.
    Kolesnik MV; Fedorova I; Karneyeva KA; Artamonova DN; Severinov KV
    Biochemistry (Mosc); 2021 Oct; 86(10):1301-1314. PubMed ID: 34903162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR technologies for bacterial systems: Current achievements and future directions.
    Choi KR; Lee SY
    Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
    Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
    Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.